A trial in a Delaware Court this week will determine if Fresenius can cancel its $4.3 billion buyout of competitor Akorn.
The FDA issued a warning letter after an inspection of the China plant where Zhuhai United Laboratories makes sterile drugs.
Biotech Rubius Therapeutics will invest large chunk of its recently raised $220 million to build a manufacturing facility.
Sanofi will close a plant in France with 50 employees and has pledged to address pollution issues there.
Zhejiang Huahai Pharmaceutical informed the EMA that it had identified a chemical that might lead to cancer in its valsartan provided to the European market.
Novartis has recalled 11 drugs from the U.S. because their packaging is not child proof. A child broke into the blister pack of an antipsychotic drug.
Boehringer Ingelheim is expanding the $77 million contract biologics plant it opened last year in Shanghai.
Fermion Oy has completed an expansion project that will increase capacity at its Hanko plant by 50%.
The FDA has issued a warning letter for a Sichuan Friendly Pharmaceutical plant at Neijiang, Sichuan.
Foshan Jinxiong Technology has been on an import alert list since February, banning all of its products from entering the U.S.